GO:0045893 positive regulation of DNA-templated transcription: Activation Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045893 describes any process that activates or increases the frequency, rate or extent of DNA-templated transcription, making it a central node in gene expression control.
• Positive regulation of transcription is executed by sequence-specific transcription factors, coactivators, chromatin remodelers and RNA polymerase II machinery that converge on promoters and enhancers.
• Dysregulation of transcriptional activation is a hallmark of cancer, where oncogenic transcription factors and chromatin regulators drive proliferation and therapy resistance [1,2].
• Chromatin remodeling complexes such as SMARCA5-containing SWI/SNF are stabilized by deubiquitinases like USP3, directly linking post-translational modification to transcriptional activation and DNA damage response.
• Pathway-level mutational signatures affecting transcriptional programs can predict breast cancer outcomes and reveal therapeutic targets.
• CRISPR-based knockout, point mutation, knock-in and overexpression models are essential to causally test how individual regulators contribute to GO:0045893 in disease contexts [1,2].
Description
Positive regulation of DNA-templated transcription (GO:0045893) is the biological process that activates or increases the frequency, rate or extent of transcription from a DNA template. It encompasses the recruitment and activation of RNA polymerase II at gene promoters, the assembly of transcription factor complexes on enhancers, and the chromatin modifications that render regulatory regions accessible. Because transcription is the first step in gene expression, its positive regulation determines which proteins a cell produces, how it responds to signals, and how it adapts during development and disease [1,2]. Researchers study GO:0045893 to understand normal cell fate decisions and to identify therapeutic vulnerabilities in cancer and other diseases where transcriptional programs are rewired [1,2]. Experimental evidence shows that transcriptional coactivators and chromatin remodelers are frequently stabilized or overexpressed in tumors, reinforcing the importance of this process as a drug target. Computational analyses of pathway-level mutational signatures further demonstrate that transcriptional activation pathways carry prognostic information in breast cancer.
positive regulation of DNA-templated transcription At A Glance
| GO ID | GO:0045893 |
|---|---|
| GO term | positive regulation of DNA-templated transcription |
| Ontology | biological_process |
| Synonym | activation of transcription, DNA-dependent; positive regulation of transcription, DNA-templated; transcription activator activity; upregulation of gene-specific transcription |
| Major function | Activates or increases the frequency, rate or extent of DNA-templated transcription |
| Biological context | Gene expression control, development, cell cycle, stress response, oncogenesis |
| Key molecular players | Sequence-specific transcription factors, coactivators (e.g., SMARCA5-containing complexes), RNA polymerase II, chromatin modifiers |
| Disease relevance | Cancer, therapy resistance, developmental disorders, metabolic disease |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, ChIP-seq, reporter assays, pathway mutational signature analysis |
What Is GO:0045893?
GO:0045893 is defined by QuickGO as any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription. In practical terms, it covers the molecular events that switch a gene from a low or inactive transcriptional state to a higher active state, including transcription factor binding, coactivator recruitment, chromatin opening, and RNA polymerase II elongation activation.
Why Is positive regulation of DNA-templated transcription Important in Cell Biology?
Positive regulation of DNA-templated transcription is important because it determines the timing and magnitude of gene expression programs that control cell identity, proliferation, differentiation and stress responses. When this process is constitutively activated, oncogenes are overexpressed and tumor suppressors may be silenced, contributing to cancer initiation and chemotherapy resistance [1,2]. Understanding how transcriptional activation is achieved mechanistically provides a rational basis for designing inhibitors of transcription factors, coactivators and chromatin remodelers, and for interpreting pathway-level mutational signatures that predict patient outcomes.
• Controls the first and most regulated step of gene expression, shaping the proteome of every cell.
• Drives developmental cell fate decisions by activating lineage-specific gene programs.
• Is frequently hijacked in cancer to overexpress oncogenes and survival factors [1,2].
• Contributes to chemotherapy resistance through stabilization of chromatin remodelers such as SMARCA5 by USP3.
• Pathway-level mutational signatures in transcriptional activation pathways predict breast cancer outcomes.
• Provides druggable nodes including deubiquitinases, chromatin remodelers and transcription factors [1,2].
• Is essential for immune and inflammatory gene activation in response to pathogens and cytokines.
• Underlies epigenetic plasticity and cell state transitions in metastasis and therapy escape [1,2].
• Serves as a functional readout for CRISPR screens testing gene regulatory networks.
• Links DNA damage response to transcriptional reprogramming via chromatin remodeler stability.
What Happens During positive regulation of DNA-templated transcription?
Signal integration and transcription factor activation
In simple terms: First, signals tell transcription factors to turn genes on.
Positive regulation begins when extracellular or intracellular signals activate sequence-specific transcription factors, allowing them to bind cognate DNA elements in promoters and enhancers. Post-translational modifications such as phosphorylation and ubiquitination regulate the stability and activity of these factors and their cofactors. For example, the deubiquitinase USP3 stabilizes SMARCA5, a chromatin remodeler that supports transcriptional activation and DNA damage response. This step ensures that transcriptional activation is coupled to appropriate cellular cues.
Chromatin remodeling and enhancer accessibility
In simple terms: The DNA packaging must be opened so the transcription machinery can access genes.
ATP-dependent chromatin remodeling complexes, including SWI/SNF family members such as SMARCA5, slide and evict nucleosomes to create accessible regulatory elements. This remodeling is required for enhancer-promoter communication and for recruitment of coactivators. Loss of remodeler stability impairs transcriptional activation and sensitizes cells to DNA-damaging agents.
Coactivator recruitment and RNA polymerase II initiation
In simple terms: Helper proteins bring RNA polymerase to the start of the gene and switch it on.
Once chromatin is accessible, coactivators and the Mediator complex bridge transcription factors to RNA polymerase II at core promoters. This leads to assembly of the preinitiation complex, phosphorylation of the RNA polymerase II C-terminal domain, and transition to elongation. Positive regulation of transcription therefore requires coordinated assembly of a large multiprotein machine.
Elongation, termination and feedback control
In simple terms: After switching on, the gene must be transcribed efficiently and then shut off appropriately.
Positive regulation extends into elongation, where positive transcription elongation factor b (P-TEFb) and other kinases promote productive RNA synthesis. Termination and feedback mechanisms prevent runaway transcription and allow rapid re-regulation. Dysregulation at any of these steps can shift gene expression programs toward oncogenic states [1,2].
Key Genes Involved in GO:0045893 positive regulation of DNA-templated transcription
The following genes and proteins are experimentally implicated in positive regulation of DNA-templated transcription and related disease biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMARCA5 | ATP-dependent chromatin remodeler supporting transcriptional activation and DNA damage response | Stabilized by USP3; target for chemotherapy resistance studies |
| USP3 | Deubiquitinase that stabilizes SMARCA5 | Promotes DNA damage response and chemotherapy resistance in prostate cancer |
| HIC1 | Transcriptional repressor with roles in development and cancer | SNP analysis reveals variants affecting transcriptional regulation |
| KIF2C | Kinesin involved in chromosome segregation and transcriptional networks | Aberrantly methylated and pro-tumorigenic in melanoma |
| KIF1A | Kinesin motor with gene regulation network in ovarian carcinoma | Bioinformatics analysis of expression and regulatory network |
| ATAD2 | Chromatin-associated ATPase and transcriptional coactivator | Deficiency impairs spermatogenesis in mice |
| RPE65 | Retinal pigment epithelium protein with stress-responsive transcription | Transcriptome profiling under oxidative stress |
| tRNA-derived fragments | Small RNAs influencing podocyte differentiation and transcription | Contribute to podocyte differentiation |
| Breast cancer pathway genes | Pathway-level mutational signatures affecting transcription | Predict outcomes and reveal therapeutic targets |
| DNA damage response genes | Coordinate transcriptional activation with repair | Linked to chemotherapy resistance |
| Chromatin remodeler complex subunits | Regulate nucleosome positioning and gene activation | Targets in cancer and fertility studies [1,6] |
| Transcription factor networks | Bind enhancers and promoters to activate genes | Central to oncogenic transcription [1,2] |
| Coactivator complexes | Bridge transcription factors to RNA polymerase II | Therapeutic targets in transcriptional addiction |
| RNA polymerase II | Catalyzes DNA-templated RNA synthesis | Core machinery of GO:0045893 |
| Mediator complex | Integrates signals from enhancer-bound factors | Required for positive transcriptional regulation |
| P-TEFb | Kinase promoting transcriptional elongation | Regulates productive transcription |
| Histone modifying enzymes | Alter chromatin marks to permit activation | Epigenetic drug targets |
| Deubiquitinases | Stabilize transcriptional regulators | Modulate chemotherapy response |
How Is positive regulation of DNA-templated transcription Regulated?
Positive regulation of DNA-templated transcription is itself tightly regulated by post-translational modifications, including ubiquitination and deubiquitination. USP3 deubiquitinates and stabilizes SMARCA5, thereby sustaining chromatin remodeling and transcriptional activation during DNA damage response. Pathway-level mutational signatures indicate that multiple components of transcriptional activation pathways are coordinately altered in breast cancer, suggesting network-level regulation. Additional layers include phosphorylation of transcription factors and RNA polymerase II, and feedback from elongation complexes.
positive regulation of DNA-templated transcription and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| USP3 | Prostate cancer chemotherapy resistance | Knockout and overexpression in prostate cancer cell lines |
| SMARCA5 | DNA damage response and transcriptional activation | Point mutation of catalytic domain and tagged knock-in |
| KIF2C | Melanoma tumorigenesis | Knockout in melanoma cells and methylation analysis |
| ATAD2 | Spermatogenesis and fertility | Knockout mouse model |
| HIC1 | Developmental and cancer-related transcriptional regulation | SNP knock-in and reporter assays |
Cancer and chemotherapy resistance
Constitutive activation of transcription drives oncogene expression and survival programs in multiple cancers [1,2]. In prostate cancer, USP3 stabilizes SMARCA5 to promote DNA damage response and chemotherapy resistance, directly linking positive transcriptional regulation to treatment failure. Pathway-level mutational signatures in breast cancer predict outcomes and reveal transcriptional activation as a therapeutic target.
Melanoma and epigenetic dysregulation
Aberrant DNA methylation and transcriptional activation contribute to melanoma progression, with KIF2C identified as pro-tumorigenic and aberrantly methylated. These findings highlight how epigenetic changes converge on positive regulation of transcription to drive tumor phenotypes.
Reproductive and developmental disorders
ATAD2 deficiency impairs spermatogenesis in mice, demonstrating that transcriptional coactivators are required for normal germ cell development. Computational analysis of HIC1 SNPs further suggests that sequence variants in transcriptional regulators can affect development and disease susceptibility.
Metabolic and oxidative stress responses
Transcriptome profiling of retinal pigment epithelial cells under hydrogen peroxide stress reveals widespread changes in gene activation programs. tRNA-derived fragments contribute to podocyte differentiation, illustrating how small RNAs intersect with transcriptional regulation in kidney biology.
From positive regulation of DNA-templated transcription-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate transcriptional regulator required for gene activation? | CRISPR knockout cell line followed by RNA-seq |
| Does a specific amino acid change alter coactivator function? | CRISPR point mutation knock-in |
| How does a fusion or tag affect chromatin binding? | Tagged knock-in (e.g., GFP or HiBiT) |
| Does overexpression drive oncogenic transcription? | Doxycycline-inducible overexpression [1,2] |
| Which pathways cooperate to activate transcription? | CRISPR library screening with pathway readouts |
| Can a transcriptional signature predict drug response? | Patient-derived organoids and pathway mutational signature analysis |
How to Study the positive regulation of DNA-templated transcription Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Readout of transcriptional activation after perturbation [1,2] |
| ChIP-seq | Transcription factor and chromatin mark binding | Mapping regulatory elements |
| ATAC-seq | Chromatin accessibility | Assessing enhancer and promoter opening |
| Luciferase reporter assay | Promoter/enhancer activity | Validating transcriptional activation |
| CRISPR knockout | Loss-of-function effects | Testing requirement for transcriptional regulators |
| CRISPR point mutation knock-in | Effect of specific variants | Modeling disease-associated mutations |
| Pathway mutational signature analysis | Pathway-level genomic alterations | Predicting cancer outcomes |
| Bioinformatics gene network analysis | Regulatory interactions | Prioritizing candidate regulators |
Transcriptomic profiling
RNA-seq measures global changes in gene expression following perturbation of transcriptional regulators, providing a direct readout of GO:0045893 activity [1,2]. Differential expression and pathway enrichment analyses identify transcriptional programs affected by knockout or overexpression.
Chromatin and binding assays
ChIP-seq and ATAC-seq map transcription factor binding and chromatin accessibility, revealing how regulators such as SMARCA5 are recruited to regulatory elements. These methods connect chromatin remodeling to positive transcriptional regulation.
Reporter and functional assays
Luciferase reporters driven by target promoters or enhancers quantify transcriptional activation in response to candidate regulators. Such assays are useful for validating point mutations and knock-in models.
Computational pathway analysis
Pathway-level mutational signature analysis integrates genomic and transcriptomic data to predict outcomes and identify therapeutic targets in cancer. Bioinformatics pipelines for gene regulation networks, as applied to KIF1A in ovarian carcinoma, help prioritize transcriptional regulators for experimental validation.
How CRISPR Can Be Used to Study GO:0045893 positive regulation of DNA-templated transcription
Knockout
CRISPR knockout of transcriptional regulators such as USP3 or SMARCA5 enables loss-of-function studies to determine whether they are required for positive regulation of DNA-templated transcription and for phenotypes such as chemotherapy resistance. Knockout followed by RNA-seq reveals the gene programs dependent on each regulator.
Point Mutation
Point mutation knock-in can model disease-associated variants in transcription factors or coactivators, allowing precise testing of how single amino acid changes alter transcriptional activation. This approach is particularly useful for dissecting catalytic versus scaffolding functions of chromatin remodelers.
Knock-in
Tagged knock-in of endogenous loci with fluorescent or epitope tags permits real-time tracking of transcriptional regulator localization and interaction dynamics. Knock-in of reporter cassettes under endogenous promoters provides physiological readouts of GO:0045893 activity.
Overexpression
Overexpression models, often inducible, test whether increased levels of a transcriptional regulator are sufficient to drive oncogenic gene programs and therapy resistance [1,2]. Overexpression combined with pathway mutational signature analysis can identify cooperative drivers in breast cancer.
How EDITGENE Supports positive regulation of DNA-templated transcription Research
Researchers studying positive regulation of DNA-templated transcription-related genes often need to determine whether a candidate gene is causally involved in activating specific gene programs, and whether its loss, mutation, tagging or overexpression alters disease-relevant phenotypes. EDITGENE provides end-to-end CRISPR cell model generation and screening services to answer these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of DNA-templated transcription research.
Frequently Asked Questions About positive regulation of DNA-templated transcription
What is GO:0045893 positive regulation of DNA-templated transcription?
GO:0045893 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription.
What genes are involved in positive regulation of DNA-templated transcription?
Genes include chromatin remodelers such as SMARCA5, deubiquitinases such as USP3, transcription factors such as HIC1, and coactivators such as ATAD2, among many others [1,4,6].
How is positive regulation of transcription linked to cancer?
Constitutive activation of transcription drives oncogene expression and therapy resistance; for example, USP3 stabilizes SMARCA5 to promote chemotherapy resistance in prostate cancer [1,2].
What experimental methods study GO:0045893?
Common methods include RNA-seq, ChIP-seq, ATAC-seq, luciferase reporter assays, CRISPR knockout and point mutation knock-in, and pathway mutational signature analysis [1,2].
What is the role of SMARCA5 in transcriptional activation?
SMARCA5 is an ATP-dependent chromatin remodeler that supports transcriptional activation and DNA damage response, and its stability is regulated by USP3.
Can CRISPR knockout help study transcriptional regulators?
Yes, CRISPR knockout of regulators such as USP3 or SMARCA5 followed by RNA-seq reveals the gene programs they control and their role in disease phenotypes.
What are pathway-level mutational signatures in breast cancer?
They are computational signatures that summarize mutations across transcriptional activation pathways and can predict patient outcomes and reveal therapeutic targets.
How does ATAD2 relate to transcription and fertility?
ATAD2 is a chromatin-associated coactivator, and its deficiency impairs spermatogenesis in mice, linking transcriptional regulation to fertility.
What is the difference between knockout, knock-in and overexpression models?
Knockout removes gene function, knock-in introduces specific sequences or mutations, and overexpression increases gene dosage; each answers different causal questions about GO:0045893.
Why is positive regulation of transcription a drug target?
Because it controls oncogenic gene programs and therapy resistance, inhibiting key coactivators or chromatin remodelers may reverse malignant phenotypes [1,2].
Conclusion
Positive regulation of DNA-templated transcription (GO:0045893) is a fundamental biological process that governs gene expression programs in health and disease. Mechanistic studies have revealed key roles for chromatin remodelers, deubiquitinases and coactivators such as SMARCA5, USP3 and ATAD2 in activating transcription and driving cancer phenotypes [1,6]. Pathway-level analyses further show that transcriptional activation signatures carry prognostic value and can nominate therapeutic targets. CRISPR-based models, including knockout, point mutation, knock-in and overexpression, are indispensable for causally testing these regulators and for translating findings into new treatments.
References
- 1. Li S et al.. 2024. USP3 promotes DNA damage response and chemotherapy resistance through stabilizing and deubiquitinating SMARCA5 in prostate cancer.. Cell Death Dis 15(11):790 PMID: 39500888
- 2. Posta M et al.. 2025. Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets.. Br J Pharmacol 182(23):5734-5747 PMID: 41057034
- 3. Shi H et al.. 2020. tRNA-derived fragments (tRFs) contribute to podocyte differentiation.. Biochem Biophys Res Commun 521(1):1-8 PMID: 31629473
- 4. Annanya A et al.. 2024. Computational Analysis of Single Nucleotide Polymorphisms in Human HIC1 Gene.. Cureus 16(3):e56664 PMID: 38646326
- 5. Huang CH et al.. 2022. Identification of aberrantly methylated differentially expressed genes and pro-tumorigenic role of KIF2C in melanoma.. Front Genet 13:817656 PMID: 35991567
- 6. Wu R et al.. 2026. ATAD2 deficiency leads to subfertility by impairing spermatogenesis in mice.. J Reprod Dev 72(1):24-33 PMID: 41443838
- 7. Wu X et al.. 2022. The transcriptome profile of RPE cells by the fullerenol against hydrogen peroxide stress.. Front Med (Lausanne) 9:996280 PMID: 36186803
- 8. Lu X et al.. 2021. Bioinformatics Analysis of KIF1A Expression and Gene Regulation Network in Ovarian Carcinoma.. Int J Gen Med 14:3707-3717 PMID: 34321916
